$SLDB

Solid Biosciences Inc.

CIK:0001707502|SEC Filings

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Operating expenses:
Research and development	$ 44,265	$ 32,415	$ 90,405	$ 63,329
General and administrative	13,119	9,278	24,287	18,416
Total operating expenses	57,384	41,693	114,692	81,745
Loss from operations	(57,384)	(41,693)	(114,692)	(81,745)
Other income, net:
Interest income	3,221	2,966	5,285	5,266
Interest expense		(60)		(128)
Change in fair value of derivative liabilities	(850)	(900)	(2,500)	(2,550)
Other income, net	214	207	371	395
Total other income, net	2,585	2,213	3,156	2,983
Net loss	$ (54,799)	$ (39,480)	$ (111,536)	$ (78,762)
Net loss per share, basic	$ (0.38)	$ (0.42)	$ (0.88)	$ (0.98)
Net loss per share, diluted	$ (0.38)	$ (0.42)	$ (0.88)	$ (0.98)
Weighted average shares of common stock outstanding used to compute basic net loss per share	143,688,701	94,140,286	126,843,665	80,317,588
Weighted average shares of common stock outstanding, used to compute diluted net loss per share	143,688,701	94,140,286	126,843,665	80,317,588

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities:
Net loss	$ (111,536)	$ (78,762)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of discount on available-for-sale securities	(1,984)	(800)
Equity-based compensation expense	10,768	6,486
Depreciation and amortization expense	786	793
Non-cash lease expense	1,257	1,162
Change in fair value of derivative liabilities	2,500	2,550
Other	25	55
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(324)	(2,060)
Accounts payable	1,139	467
Change in operating lease liability	(1,006)	(848)
Accrued expenses and other liabilities	(1,442)	1,695
Net cash used in operating activities	(99,817)	(69,262)
Cash flows from investing activities:
Purchases of property and equipment	(315)	(503)
Proceeds from maturities of available-for-sale securities	146,880	69,000
Purchases of available-for-sale securities	(235,396)	(128,777)
Other	0	85
Net cash used in investing activities	(88,831)	(60,195)
Cash flows from financing activities:
Proceeds from issuance of common stock and pre-funded warrants in public offering, net of underwriting discounts and commissions	0	189,637
Payments of common stock and pre-funded warrants issuance costs in public offering	0	(1,681)
Proceeds from issuance of common stock and pre-funded warrants in private placement	239,972	0
Payments of common stock and pre-funded warrants issuance costs in private placement	(13,644)	0
Proceeds from issuance of common stock in at-the-market public offering, net of sales commissions	60,801	246
Proceeds from exercises of common stock options	78	6
Employee stock purchase plan purchases	291	196
Payments of principal portion of finance lease obligations	0	(277)
Net cash provided by financing activities	287,498	188,127
Net increase in cash, cash equivalents, and restricted cash	98,850	58,670
Cash, cash equivalents, and restricted cash at beginning of period	61,890	82,187
Cash, cash equivalents, and restricted cash at end of period	160,740	140,857
Supplemental disclosure of cash flow information:
Cash paid for Interest	0	128
Supplemental disclosure of non-cash investing, financing and operating activities:
Common stock issued as payment for developmental milestone consideration	7,500	5,000
Property and equipment purchases included in accounts payable and accrued expenses	$ 285	$ 0

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 159,394	$ 59,900
Available-for-sale securities	218,284	127,950
Prepaid expenses and other current assets	16,792	16,384
Restricted cash, current	638	1,222
Total current assets	395,108	205,456
Non-current assets:
Operating lease, right-of-use assets	20,667	21,924
Property and equipment, net	3,959	4,169
Other non-current assets	138	223
Restricted cash, net of current portion	708	768
Total non-current assets	25,472	27,084
Total assets	420,580	232,540
Current liabilities:
Accounts payable	4,360	3,224
Accrued expenses and other current liabilities	17,790	18,945
Operating lease liabilities, current	2,234	2,103
Derivative liabilities	4,200	9,200
Total current liabilities	28,584	33,472
Non-current liabilities:
Operating lease liabilities, net of current portion	17,921	19,058
Total non-current liabilities	17,921	19,058
Total liabilities	46,505	52,530
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at June 30, 2026 and December 31, 2025; no shares issued or outstanding at June 30, 2026 and December 31, 2025
Common stock, $0.001 par value; 480,000,000 and 240,000,000 shares authorized at June 30, 2026 and December 31, 2025; 105,125,366 and 78,967,888 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	105	79
Additional paid-in capital	1,443,394	1,137,654
Accumulated other comprehensive income	(113)	52
Accumulated deficit	(1,069,311)	(957,775)
Total stockholders’ equity	374,075	180,010
Total liabilities and stockholders’ equity	$ 420,580	$ 232,540